Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2026 Guidance

Aveanna delivers strong revenue and profit growth, raising 2026 guidance on solid operating momentum.

What the company is saying

Aveanna Healthcare Holdings Inc. reports robust financial results for the three and nine months ended October 3, 2026, highlighting 11.8% year-over-year revenue growth for the quarter and 13.7% for the nine-month period. The company attributes these gains to organic growth across all three business segments, with the PDS segment contributing the largest increase. CEO Jeff Shaner and CFO Matt Buckhalter emphasize the effectiveness of their Preferred Payor and Government Affairs strategies, as well as disciplined execution and cash flow generation. The company raises its full-year 2026 guidance to revenue of greater than $2.695 billion and Adjusted EBITDA of greater than $374 million, citing confidence in the outlook. Management explains that net income guidance is withheld due to volatility in certain required inputs, specifically fair value adjustments on interest rate caps. The tone is confident and data-driven, with a focus on operational execution and sustained year-over-year improvement.

What the data suggests

Revenue for the third quarter reached $695.5 million, up from $621.9 million a year earlier, with the PDS segment accounting for $59.8 million of the $73.6 million increase. Gross margin for the quarter was $226.8 million, or 32.6% of revenue, matching the prior year's margin percentage but increasing in absolute dollars. Net income for the quarter more than tripled to $45.5 million, or 6.5% of revenue, from $14.1 million, or 2.3% of revenue, a year ago. Adjusted EBITDA rose 25.0% to $100.1 million, representing 14.4% of revenue. For the nine-month period, revenue was $2,013.9 million, gross margin $650.7 million (32.3% of revenue), and net income $127.4 million (6.3% of revenue), all showing substantial year-over-year gains. Operating cash flow for the nine months was $157.5 million, with free cash flow at $141.2 million. The company holds $197.8 million in cash and has $225.6 million in undrawn revolver capacity, but total indebtedness stands at $1,521.3 million. Interest rate risk is hedged with $1.4 billion in notional caps at SOFR rates of 4.00% and 2.96%. The raised full-year guidance for revenue and Adjusted EBITDA is incremental and supported by realised results to date.

Analysis

The announcement is highly factual and proportionate, with the vast majority of claims supported by realised, audited financial results for both the three- and nine-month periods ended October 3, 2026. Key profitability metrics—net income, gross margin, adjusted EBITDA, free cash flow—are all disclosed and show clear, material improvement year-over-year. The only forward-looking statements are the modestly raised full-year revenue and Adjusted EBITDA guidance, which are incremental and not presented in an exaggerated manner. There is no evidence of narrative inflation or overstatement; the tone is positive but justified by the underlying numbers. Capital intensity is not flagged, as no new large outlays or long-dated, uncertain returns are discussed. The data quality is high, and the gap between narrative and evidence is negligible.

Risk flags

• ●Aveanna's total indebtedness is high at $1,521.3 million, which could constrain financial flexibility if operating performance weakens or interest rates rise unexpectedly. The company's reliance on interest rate caps mitigates some risk, but not all exposure is eliminated.
• ●The company does not provide net income guidance due to volatility in fair value adjustments on interest rate caps, which introduces uncertainty into bottom-line forecasting. This lack of forward-looking profit guidance may limit visibility for investors.
• ●While cash flow and liquidity are strong, the company is exposed to sector-specific risks in home healthcare, including reimbursement changes, labor shortages, and regulatory shifts, which could impact future margins and growth.
• ●A significant portion of revenue growth is concentrated in the PDS segment; any operational or regulatory disruption in this area could disproportionately affect overall results.

Bottom line

Aveanna Healthcare Holdings Inc. is delivering on its operational and financial targets, with double-digit revenue and profit growth across both the quarter and year-to-date periods. The company's raised guidance for full-year 2026 revenue and Adjusted EBITDA is credible, given the strength of realised results and the short time left in the fiscal year. Liquidity is ample, but the high debt load remains a structural risk, partially offset by hedged interest rate exposure. The absence of net income guidance introduces some uncertainty, but management's rationale is transparent. Investors should focus on the company's ability to sustain organic growth in its core segments and monitor for any signs of margin pressure or regulatory headwinds. The most important takeaway is that Aveanna's operating model is currently generating strong cash flow and profit, supporting its near-term outlook.

Announcement summary

(NASDAQ: AVAH) Aveanna Healthcare Holdings Inc. announced financial results for the three and nine-month periods ended October 3, 2026. Revenue for the three-month period ended October 3, 2026 was $695.5 million, compared to $621.9 million for the same period in 2025, an increase of $73.6 million or 11.8%. The increase in revenue was driven by a $59.8 million increase in PDS segment revenue, a $9.7 million increase in HHH segment revenue, and a $4.1 million increase in MS segment revenue. Gross margin for the three-month period was $226.8 million, or 32.6% of revenue, up from $202.8 million, or 32.6% of revenue, in the prior year, an increase of $23.9 million or 11.8%. Net income for the three-month period was $45.5 million, or 6.5% of revenue, compared to $14.1 million, or 2.3% of revenue, in the prior year. Net income per diluted share was $0.20, up from $0.06 in the prior year. Adjusted net income per diluted share was $0.23, compared to $0.15 in the prior year. Adjusted EBITDA for the three-month period was $100.1 million, or 14.4% of revenue, compared to $80.1 million, or 12.9% of revenue, an increase of $20.0 million or 25.0%. For the nine-month period ended October 3, 2026, revenue was $2,013.9 million, compared to $1,770.7 million in the prior year, an increase of $243.2 million or 13.7%. The increase in nine-month revenue was due to a $203.4 million increase in PDS segment revenue, a $28.5 million increase in HHH segment revenue, and an $11.4 million increase in MS segment revenue. Gross margin for the nine-month period was $650.7 million, or 32.3% of revenue, compared to $597.2 million, or 33.7% of revenue, an increase of $53.5 million or 9.0%. Net income for the nine-month period was $127.4 million, or 6.3% of revenue, compared to $46.3 million, or 2.6% of revenue, in the prior year. Net income per diluted share for the nine-month period was $0.57, up from $0.22 in the prior year. Adjusted net income per diluted share was $0.63, compared to $0.43 in the prior year. Adjusted EBITDA for the nine-month period was $279.9 million, or 13.9% of revenue, compared to $235.9 million, or 13.3% of revenue, an increase of $44.0 million or 18.7%. As of October 3, 2026, Aveanna had cash of $197.8 million and incremental borrowing capacity of $68.7 million under its securitization facility. The revolver was undrawn, with approximately $225.6 million of borrowing capacity and approximately $24.4 million of outstanding letters of credit. Net cash provided by operating activities was $157.5 million for the nine-month period, and free cash flow was $141.2 million. Total indebtedness as of October 3, 2026 was $1,521.3 million. Interest rate exposure under credit facilities is hedged with $520.0 million notional amount of interest rate caps at 4.00% SOFR and $880.0 million notional amount of interest rate caps at 2.96% SOFR. For the full fiscal year 2026, Aveanna raised its guidance to revenue of greater than $2.695 billion (up from greater than $2.68 billion) and Adjusted EBITDA of greater than $374 million (up from greater than $365 million). The company does not provide guidance on net income due to volatility in certain required inputs. Jeff Shaner is Chief Executive Officer and Matt Buckhalter is Chief Financial Officer. The company uses non-GAAP financial measures including EBITDA, Adjusted EBITDA, Field contribution, Field contribution margin, Adjusted net income, Adjusted net income per diluted share, and Free cash flow, with reconciliations included in the financial tables.

Disagree with this article?